Di Carlo Claudia, Brandi Jessica, Cecconi Daniela
Department of Biotechnology, Proteomics and Mass Spectrometry Laboratory, University of Verona, Verona 37134, Italy.
World J Stem Cells. 2018 Nov 26;10(11):172-182. doi: 10.4252/wjsc.v10.i11.172.
Pancreatic ductal adenocarcinoma is one of the most aggressive solid tumours of the pancreas, characterised by a five-year survival rate less than 8%. Recent reports that pancreatic cancer stem cells (PCSCs) contribute to the tumorigenesis, progression, and chemoresistance of pancreatic cancer have prompted the investigation of new therapeutic approaches able to directly target PCSCs. In the present paper the non-cancer related drugs that have been proposed to target CSCs that could potentially combat pancreatic cancer are reviewed and evaluated. The role of some pathways and deregulated proteins in PCSCs as new therapeutic targets are also discussed with a focus on selected specific inhibitors. Finally, advances in the development of nanoparticles for targeting PCSCs and site-specific drug delivery are highlighted, and their limitations considered.
胰腺导管腺癌是胰腺最具侵袭性的实体瘤之一，其五年生存率低于8%。最近有报道称，胰腺癌干细胞（PCSCs）促成了胰腺癌的发生、发展和化疗耐药性，这促使人们去研究能够直接靶向PCSCs的新治疗方法。在本文中，对已被提出用于靶向可能对抗胰腺癌的CSCs的非癌症相关药物进行了综述和评估。还讨论了一些信号通路和失调蛋白在PCSCs中作为新治疗靶点的作用，并重点关注了选定的特异性抑制剂。最后，强调了用于靶向PCSCs和定点给药的纳米颗粒开发进展，并考虑了它们的局限性。
